A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses

  1. Alexandra Tauzin
  2. Shang Yu Gong
  3. Mark M. Painter
  4. Rishi R. Goel
  5. Debashree Chatterjee
  6. Guillaume Beaudoin-Bussières
  7. Lorie Marchitto
  8. Marianne Boutin
  9. Annemarie Laumaea
  10. James Okeny
  11. Gabrielle Gendron-Lepage
  12. Catherine Bourassa
  13. Halima Medjahed
  14. Guillaume Goyette
  15. Justine C. Williams
  16. Yuxia Bo
  17. Laurie Gokool
  18. Chantal Morrisseau
  19. Pascale Arlotto
  20. Renée Bazin
  21. Judith Fafard
  22. Cécile Tremblay
  23. Daniel E. Kaufmann
  24. Gaston De Serres
  25. Marceline Côté
  26. Ralf Duerr
  27. Valérie Martel-Laferrière
  28. Allison R. Greenplate
  29. E. John Wherry
  30. Andrés Finzi
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Due to the recrudescence of SARS-CoV-2 infections worldwide, mainly caused by Omicron BA.1 and BA.2 variants of concern, several jurisdictions are administering a mRNA vaccine boost. Here, we analyzed humoral responses induced after the second and third doses of mRNA vaccine in naïve and previously-infected donors who received their second dose with an extended 16-week interval. We observed that the extended interval elicited robust humoral responses against VOCs, but this response was significantly diminished 4 months after the second dose. Administering a boost to these individuals brought back the humoral responses to the same levels obtained after the extended second dose. Interestingly, we observed that administering a boost to individuals that initially received a short 3-4 weeks regimen elicited humoral responses similar to those elicited in the long interval regimen. Nevertheless, humoral responses elicited by the boost in naïve individuals did not reach those present in previously-infected vaccinated individuals.

Related articles

Related articles are currently not available for this article.